Boston, Massachusetts 2021-09-19 09:45:52 –
what is that?
STAT + is STAT’s premium subscription service for detailed coverage and analysis of biotechnology, pharmaceuticals, policies and life sciences. The award-winning team covers Wall Street news, policy development in Washington, early scientific advances and clinical trials, and the medical turmoil since Silicon Valley.
What is included?
- Daily reports and analysis
- The most comprehensive industry coverage from a strong team of reporters
- Subscriber-only newsletter
- Daily newsletter briefly describing the most important industry news of the day
- STAT + conversation
- Weekly opportunities to interact with reporters and industry-leading professionals in live video conversations
- Exclusive industry event
- Premium access to subscriber-only networking events nationwide
- The best reporter in the industry
- The most trusted and connected news room in the healthcare industry
- And much more
- Exclusive interviews with industry leaders, profiles, and premium tools such as CRISPR Trackr.
window.statFbq = function( eventName, parameters ) {
jQuery.ajax( {
url: ‘/wp-json/stat-analytics/v1/facebook-pixel’,
type: ‘POST’,
data: {
event_name: !eventName ? null : eventName,
parameters: !parameters ? {} : parameters,
source_url: window.location.href
},
success: function( data, textStatus, jqXHR ) {
//console.log( data );
},
error: function ( jqXHR, textStatus, errorThrown ) {
//console.log( jqXHR );
}
} );
};
jQuery( window ).on( ‘load’, function() {
if ( !window.bgmpGdpr || window.bgmpGdpr.isOptedOut() ) {
return;
}
!function(f,b,e,v,n,t,s){if(f.fbq)return;n=f.fbq=function(){n.callMethod?
n.callMethod.apply(n,arguments):n.queue.push(arguments)};if(!f._fbq)f._fbq=n;
n.push=n;n.loaded=!0;n.version=’2.0′;n.queue=[];t=b.createElement(e);t.async=!0;
t.src=v;s=b.getElementsByTagName(e)[0];s.parentNode.insertBefore(t,s)}(window,
document,’script’,’https://connect.facebook.net/en_US/fbevents.js’);
fbq( ‘init’, ‘436331036555416’ );
fbq( ‘track’, ‘PageView’ );
if ( ‘object’ === typeof mc4wp && mc4wp.forms ) {
mc4wp.forms.on( ‘subscribed’, function() {
// Successful MC4WP newsletter signup AJAX form submission.
statFbq( ‘Lead’ );
} );
}
statFbq( ‘ViewContent’ );
} );
New colon cancer study suggests Mirati has the best KRAS-blocking drug Source link New colon cancer study suggests Mirati has the best KRAS-blocking drug
The post New colon cancer study suggests Mirati has the best KRAS-blocking drug – Boston, Massachusetts appeared first on Eminetra.
